{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T08:42:16Z","timestamp":1792917736143,"version":"4.5.0"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.pnpbp.2018.06.005","type":"journal-article","created":{"date-parts":[[2018,6,15]],"date-time":"2018-06-15T05:00:28Z","timestamp":1529038828000},"page":"245-254","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Oral N-acetylcysteine in the treatment of obsessive-compulsive disorder: A systematic review of the clinical evidence"],"prefix":"10.1016","volume":"86","author":[{"given":"Jos\u00e9 Paulo","family":"Couto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2018.06.005_bb0005","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0022-3956(00)00022-4","article-title":"fMRI of neuronal activation with symptom provocation in unmedicated patients with obsessive compulsive disorder","volume":"34","author":"Adler","year":"2000","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0010","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1097\/JCP.0b013e318272677d","article-title":"N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial","volume":"32","author":"Afshar","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0015","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jpsychires.2017.06.004","article-title":"Buprenorphine augmentation improved symptoms of OCD, compared to placebo - results from a randomized, double-blind and placebo-controlled clinical trial","volume":"94","author":"Ahmadpanah","year":"2017","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0020","series-title":"Diagnostic and Statistical Manual of Mental Disorders. Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013"},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0025","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1017\/S0033291713000470","article-title":"Age of onset in obsessive-compulsive disorder: admixture analysis with a large sample","volume":"44","author":"Anholt","year":"2014","journal-title":"Psychol. Med."},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0035","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.coph.2007.04.005","article-title":"N-acetylcysteine - a safe antidote for cysteine\/glutathione deficiency","volume":"7","author":"Atkuri","year":"2007","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0045","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/13651501.2012.667114","article-title":"Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care","volume":"16","author":"Bandelow","year":"2012","journal-title":"Int. J. Psychiatry Clin. Pract."},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0050","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/archpsyc.1992.01820090009002","article-title":"Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder","volume":"49","author":"Baxter","year":"1992","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0055","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1159\/000306591","article-title":"Relationship of possible stress-related biochemical markers to oxidative\/antioxidative status in obsessive-compulsive disorder","volume":"61","author":"Behl","year":"2010","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0060","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.tips.2013.01.001","article-title":"The promise of N-acetylcysteine in neuropsychiatry","volume":"34","author":"Berk","year":"2013","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0065","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1038\/npp.2009.77","article-title":"Anti-brain autoantibodies and altered excitatory neurotransmitters in obsessive-compulsive disorder","volume":"34","author":"Bhattacharyya","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0070","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/mp.2009.50","article-title":"Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder","volume":"15","author":"Bloch","year":"2010","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0075","first-page":"45","article-title":"Toxicological, pharmacokinetic and metabolic studies on acetylcysteine","volume":"111","author":"Bonanomi","year":"1980","journal-title":"Eur. J. Respir. Dis. Suppl."},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0080","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1227\/NEU.0b013e31827b9c7c","article-title":"Beneficial effect of subsequent lesion procedures after nonresponse to initial cingulotomy for severe, treatment-refractory obsessive-compulsive disorder","volume":"72","author":"Bourne","year":"2013","journal-title":"Neurosurgery"},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0085","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1001\/archpsyc.1996.01830070041008","article-title":"Functional magnetic resonance imaging of symptom provocation in obsessive-compulsive disorder","volume":"53","author":"Breiter","year":"1996","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0090","first-page":"207","article-title":"Textbook of evolutionary psychiatry and psychosomatic medicine","volume":"1","author":"Br\u00fcne","year":"2015","journal-title":"The Origins of Psychopathology."},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0095","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1369\/jhc.5A6840.2006","article-title":"Distribution of the cystine\/glutamate antiporter system xc- in the brain, kidney, and duodenum","volume":"54","author":"Burdo","year":"2006","journal-title":"J. Histochem. Cytochem."},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0100","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.biopsych.2004.09.029","article-title":"Amygdala responses to human faces in obsessive-compulsive disorder","volume":"56","author":"Cannistraro","year":"2004","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0105","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1038\/sj.npp.1300733","article-title":"Glutamatergic dysfunction in OCD","volume":"30","author":"Chakrabarty","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0110","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s12291-009-0035-9","article-title":"Study of oxidative stress in obsessive compulsive disorder in response to treatment with Fluoxetine","volume":"24","author":"Chakraborty","year":"2009","journal-title":"Indian J. Clin. Biochem."},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0115","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.pnpbp.2009.01.001","article-title":"Correlation between lipid peroxidation-induced TBARS level and disease severity in obsessive-compulsive disorder","volume":"33","author":"Chakraborty","year":"2009","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0120","doi-asserted-by":"crossref","first-page":"e766","DOI":"10.4088\/JCP.16m11101","article-title":"Randomized, double-blind. placebo-controlled trial of N-acetylcysteine augmentation for treatment-resistant obsessive-compulsive disorder","volume":"78","author":"Costa","year":"2017","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0125","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S1054-3589(08)60985-0","article-title":"N-acetylcysteine: pharmacological considerations and experimental and clinical applications","volume":"38","author":"Cotgreave","year":"1997","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0130","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1046\/j.1365-2362.2000.00736.x","article-title":"N-acetylcysteine replenishes glutathione in HIV infection","volume":"30","author":"De Rosa","year":"2000","journal-title":"Eur. J. Clin. Investig."},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0135","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1176\/appi.ajp.159.2.269","article-title":"Prospective long-term follow-up of 44 patients who received cingulotomy for treatment-refractory obsessive-compulsive disorder","volume":"159","author":"Dougherty","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0140","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.pnpbp.2006.03.034","article-title":"Examination of free radical metabolism and antioxidant defence system elements in patients with obsessive-compulsive disorder","volume":"30","author":"Ersan","year":"2006","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0145","first-page":"134","article-title":"Efficacy of N-acetylcysteine augmentation on obsessive compulsive disorder: a multicenter randomized double blind placebo controlled clinical trial","volume":"12","author":"Ghanizadeh","year":"2017","journal-title":"Iran. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0150","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/j.bcp.2012.09.010","article-title":"N-acetylcysteine ethyl ester (NACET): a novel lipophilic cell-permeable cysteine derivative with an unusual pharmacokinetic feature and remarkable antioxidant potential","volume":"84","author":"Giustarini","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0155","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.drudis.2007.12.009","article-title":"Serotoninergic mechanisms in the treatment of obsessive-compulsive disorder","volume":"13","author":"Goddard","year":"2008","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0160","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/npp.2012.182","article-title":"Translational research in OCD: circuitry and mechanisms","volume":"38","author":"Haber","year":"2013","journal-title":"Neuropsychopharmacology"},{"issue":"633\u2013640","key":"10.1016\/j.pnpbp.2018.06.005_bb0165","article-title":"In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD)","volume":"228","author":"Haghighi","year":"2013","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0170","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1600-0447.2006.00940.x","article-title":"Reduced midbrain-pons serotonin transporter binding in patients with obsessive-compulsive disorder","volume":"115","author":"Hasselbalch","year":"2007","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0175","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.pscychresns.2005.07.002","article-title":"Serotonin and dopamine transporter imaging in patients with obsessive-compulsive disorder","volume":"140","author":"Hesse","year":"2005","journal-title":"Psychiatry Res."},{"issue":"8","key":"10.1016\/j.pnpbp.2018.06.005_bb0180","first-page":"187","article-title":"Cochrane handbook for systematic reviews of interventions, version 5.1.0","volume":"1","author":"Higgins","year":"2011","journal-title":"Cochrane Collab"},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0185","author":"Howick"},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0190","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.psychres.2017.11.080","article-title":"Patients with OCD report lower quality of life after controlling for expert-rated symptoms of depression and anxiety","volume":"260","author":"Jahangard","year":"2017","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0195","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1521\/bumc.65.1.4.18714","article-title":"An update on obsessive-compulsive disorder","volume":"65","author":"Jenike","year":"2001","journal-title":"Bull. Menn. Clin."},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0200","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1056\/NEJMcp031002","article-title":"Clinical practice Obsessive-compulsive disorder","volume":"350","author":"Jenike","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0205","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.neuroscience.2008.06.010","article-title":"Blunted cystine-glutamate antiporter function in the nucleus accumbens promotes cocaine-induced drug seeking","volume":"155","author":"Kau","year":"2008","journal-title":"Neuroscience"},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0210","first-page":"5","article-title":"Practice guideline for the treatment of patients with obsessive-compulsive disorder","volume":"164","author":"Koran","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0215","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.pneurobio.2004.03.006","article-title":"The functional neuroanatomy of the human orbitofrontal cortex: evidence from neuroimaging and neuropsychology","volume":"72","author":"Kringelbach","year":"2004","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0220","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s00213-005-0246-6","article-title":"N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder","volume":"184","author":"Lafleur","year":"2006","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0225","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/da.20669","article-title":"Obsessive-compulsive disorder: a review of the diagnostic criteria and possible subtypes and dimensional specifiers for DSM-V","volume":"27","author":"Leckman","year":"2010","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0235","article-title":"An interventional study on the clinical usefulness and outcomes of electroconvulsive therapy in medication-resistant mental disorders","volume":"8","author":"Manhas","year":"2016","journal-title":"Cureus"},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0245","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1192\/bjp.164.4.459","article-title":"Functional anatomy of obsessive-compulsive phenomena","volume":"164","author":"McGuire","year":"1994","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0250","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.tics.2011.11.003","article-title":"Obsessive-compulsive disorder: beyond segregated cortico-striatal pathways","volume":"16","author":"Milad","year":"2012","journal-title":"Trends Cogn. Sci."},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0255","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0260","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.pnpbp.2008.10.004","article-title":"Serum selenium and plasma malondialdehyde levels and antioxidant enzyme activities in patients with obsessive-compulsive disorder","volume":"33","author":"Ozdemir","year":"2009","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0265","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.pnpbp.2005.11.028","article-title":"Treatment-refractory obsessive-compulsive disorder: methodological issues, operational definitions and therapeutic lines","volume":"30","author":"Pallanti","year":"2006","journal-title":"Prog. Neuro-Psychopharmacology Biol. Psychiatry"},{"issue":"Suppl E","key":"10.1016\/j.pnpbp.2018.06.005_bb0270","first-page":"8","article-title":"Tolerability of modern antidepressants","volume":"69","author":"Papakostas","year":"2008","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0275","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/nrn3746","article-title":"Obsessive-compulsive disorder: an integrative genetic and neurobiological perspective","volume":"15","author":"Pauls","year":"2014","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0280","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/jcpt.12370","article-title":"N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled trial","volume":"41","author":"Paydary","year":"2016","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0285","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1192\/bjp.166.2.244","article-title":"[18F]FDG PET study in obsessive-compulsive disorder. A clinical\/metabolic correlation study after treatment","volume":"166","author":"Perani","year":"1995","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0290","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.pharmthera.2011.09.006","article-title":"Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment","volume":"132","author":"Pittenger","year":"2011","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0295","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/glia.1037","article-title":"Visualising the activity of the cystine-glutamate antiporter in glial cells using antibodies to aminoadipic acid, a selectively transported substrate","volume":"34","author":"Pow","year":"2001","journal-title":"Glia"},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0300","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/archgenpsychiatry.2010.70","article-title":"Meta-analytical comparison of voxel-based morphometry studies in obsessive-compulsive disorder vs other anxiety disorders","volume":"67","author":"Radua","year":"2010","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0305","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1001\/archpsyc.1994.03950010062008","article-title":"Regional cerebral blood flow measured during symptom provocation in obsessive-compulsive disorder using oxygen 15-labeled carbon dioxide and positron emission tomography","volume":"51","author":"Rauch","year":"1994","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0310","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.biopsych.2005.12.012","article-title":"Functional magnetic resonance imaging study of regional brain activation during implicit sequence learning in obsessive-compulsive disorder","volume":"61","author":"Rauch","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0315","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/mp.2008.94","article-title":"The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication","volume":"15","author":"Ruscio","year":"2010","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0320","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/S0924-9338(15)31159-7","article-title":"Complete remission of obsessive compulsive disorder after N-acetylcystein treatment","volume":"30","author":"Saraiva","year":"2015","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0325","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s40263-015-0272-9","article-title":"N-acetyl cysteine (NAC) in the treatment of obsessive-compulsive disorder: a 16-week, double-blind, randomised. Placebo-Controlled Study","volume":"29","author":"Sarris","year":"2015","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0330","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1177\/2167702616639864","article-title":"Participant characteristics as modifiers of response to N-acetyl cysteine (NAC) in obsessive-compulsive disorder","volume":"4","author":"Sarris","year":"2016","journal-title":"Clin. Psychol. Sci."},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0335","doi-asserted-by":"crossref","DOI":"10.22237\/jmasm\/1257035100","article-title":"New effect size rules of thumb","volume":"8","author":"Sawilowsky","year":"2009","journal-title":"J. Mod. Appl. Stat. Methods"},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0340","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0193-953X(05)70181-7","article-title":"Functional neuroimaging and the neuroanatomy of obsessive-compulsive disorder","volume":"23","author":"Saxena","year":"2000","journal-title":"Psychiatr. Clin. North Am."},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0345","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1192\/S0007125000297870","article-title":"Neuroimaging and frontal-subcortical circuitry in obsessive-compulsive disorder","author":"Saxena","year":"1998","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0350","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1002\/hbm.20980","article-title":"Fronto-cingulate effective connectivity in obsessive compulsive disorder: a study with fMRI and dynamic causal modeling","volume":"31","author":"Schlosser","year":"2010","journal-title":"Hum. Brain Mapp."},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0355","first-page":"728","article-title":"Fronto-striato-limbic hyperactivation in obsessive-compulsive disorder during individually tailored symptom provocation","volume":"47","author":"Simon","year":"2010","journal-title":"Psychophysiology"},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0360","first-page":"CD001765","article-title":"Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD)","author":"Soomro","year":"2008","journal-title":"Cochrane database Syst. Rev."},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0365","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/s00406-004-0489-y","article-title":"Reduced serotonin transporter-availability in obsessive-compulsive disorder (OCD)","volume":"254","author":"Stengler-Wenzke","year":"2004","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0370","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1001\/archpsyc.1989.01810060038007","article-title":"Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder","volume":"46","author":"Swedo","year":"1989","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0375","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1001\/archpsyc.1992.01820090018003","article-title":"Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder. Revisualization during pharmacotherapy","volume":"49","author":"Swedo","year":"1992","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0380","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jocrd.2012.10.003","article-title":"N-acetylcysteine augmentation in treatment resistant obsessive compulsive disorder: a case series","volume":"2","author":"Van Ameringen","year":"2013","journal-title":"J. Obsessive. Compuls. Relat. Disord."},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0385","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.pbb.2011.10.007","article-title":"The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder","volume":"100","author":"Wu","year":"2012","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0390","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1089\/cap.2014.0053","article-title":"The role of glutamatergic dysfunction in treatment-resistant obsessive-compulsive disorder: treatment of an adolescent case with N-acetylcysteine augmentation","volume":"24","author":"Yazici","year":"2014","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0395","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/JCP.0000000000000362","article-title":"N-acetylcysteine augmentation in children and adolescents diagnosed with treatment-resistant obsessive-compulsive disorder: case series","volume":"35","author":"Yazici","year":"2015","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0400","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1080\/00048670802050546","article-title":"Anterior cingulate glutamate-glutamine levels predict symptom severity in women with obsessive-compulsive disorder","volume":"42","author":"Yucel","year":"2008","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2018.06.005_bb0405","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s000180300001","article-title":"Molecular mechanisms of N-acetylcysteine actions","volume":"60","author":"Zafarullah","year":"2003","journal-title":"Cell. Mol. Life Sci."}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584618301027?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584618301027?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T19:47:40Z","timestamp":1759520860000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584618301027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":77,"alternative-id":["S0278584618301027"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2018.06.005","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral N-acetylcysteine in the treatment of obsessive-compulsive disorder: A systematic review of the clinical evidence","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2018.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}